October 26th 2022
Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.
February 1st 2020
Naoto Ueno, MD, PhD, FACP, discusses residual cancer burden and immunotherapy in inflammatory breast cancer.